Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176485 | 0.96 | FKBP1A (0.47) | FKBP1APOLBKDM4EALDH1A1MAPT | |
| SCHEMBL19171985 | 0.89 | FKBP1A (0.47) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL20310851 | 0.84 | FKBP1A (0.43) | FKBP1AKDM4EALDH1A1MAPTTSHR | |
| SCHEMBL1207488 | 0.83 | POLB (0.41) | FKBP1APOLBSMN1; SMN2 | |
| SCHEMBL4045420 | 0.83 | FKBP1A (0.51) | FKBP1APOLBKDM4EALDH1A1MAPT | |
| SCHEMBL17001994 | 0.83 | POLB (0.41) | FKBP1APOLBSMN1; SMN2 | |
| SCHEMBL12881530 | 0.82 | SMN1; SMN2 (0.42) | FKBP1AKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL3316195 | 0.82 | POLB (0.36) | FKBP1APOLBALDH1A1MAPTPKM | |
| SCHEMBL1206077 | 0.82 | POLB (0.36) | FKBP1APOLBALDH1A1MAPTPKM | |
| SCHEMBL12881542 | 0.79 | FKBP1A (0.48) | FKBP1APOLBKDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034444-A1 | SELECTED CGRP ANTAGONISTS, PROCESSES FOR PREPARING THEM AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | CALCRL, CALCR, CALCA | FKBP1A 2848/4885POLB 2511/4885KDM4E 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.